دورية أكاديمية
أعرض في EDS

Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer.

التفاصيل البيبلوغرافية
العنوان: Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer.
المؤلفون: Khan QJ; Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA. qkhan@kumc.edu, Reddy PS, Kimler BF, Sharma P, Baxa SE, O'Dea AP, Klemp JR, Fabian CJ
المصدر: Breast cancer research and treatment [Breast Cancer Res Treat] 2010 Jan; Vol. 119 (1), pp. 111-8. Date of Electronic Publication: 2009 Aug 05.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE
أسماء مطبوعة: Publication: Dordrecht : Kluwer Academic
Original Publication: The Hague ; Boston : M. Nijhoff, c1981-
مواضيع طبية MeSH: Dietary Supplements*, Antineoplastic Agents/*therapeutic use , Arthralgia/*therapy , Breast Neoplasms/*drug therapy , Fatigue/*drug therapy , Nitriles/*therapeutic use , Triazoles/*therapeutic use , Vitamin D/*analogs & derivatives , Vitamin D/*therapeutic use, Aged ; Aromatase Inhibitors/therapeutic use ; Arthralgia/drug therapy ; Arthralgia/prevention & control ; Chemotherapy, Adjuvant ; Cohort Studies ; Female ; Humans ; Letrozole ; Middle Aged ; Postmenopause ; Treatment Outcome ; Vitamin D/blood ; Vitamin D Deficiency/drug therapy
مستخلص: Vitamin D deficiency and insufficiency may contribute to musculoskeletal symptoms and bone loss observed in women taking aromatase inhibitors (AIs). This study was conducted to determine the prevalence of suboptimal vitamin D levels in women initiating adjuvant letrozole for breast cancer and to determine whether supplementation with 50,000 IU of vitamin D3 weekly could reduce musculoskeletal symptoms and fatigue in women who have suboptimal vitamin D levels. Sixty women about to begin an adjuvant AI were enrolled. Baseline 25OHD levels were obtained, and women completed symptom questionnaires. They were then started on letrozole, along with standard dose calcium and vitamin D. Four weeks later, women with baseline 25OHD levels 40 ng/ml were achieved in all 42 subjects who received 12 weeks of supplementation with 50,000 IU vitamin D3 weekly, with no adverse effects. After 16 weeks of letrozole, more women with 25OHD levels >66 ng/ml (median level) reported no disability from joint pain than did women with levels <66 ng/ml (52 vs. 19%; P = 0.026). Vitamin D deficiency and insufficiency are prevalent in post-menopausal women initiating adjuvant AI. Vitamin D3 supplementation with 50,000 IU per week is safe, significantly increases 25OHD levels, and may reduce disability from AI-induced arthralgias.
References: Cancer. 1999 Mar 1;85(5):1186-96. (PMID: 10091805)
Calcif Tissue Int. 1986 Sep;39(3):139-44. (PMID: 3093024)
Mayo Clin Proc. 2006 Mar;81(3):353-73. (PMID: 16529140)
J Clin Oncol. 2005 Aug 1;23(22):5126-37. (PMID: 15983390)
Lancet. 1998 Mar 14;351(9105):805-6. (PMID: 9519960)
Arthritis Rheum. 2004 Oct;50(10):3296-305. (PMID: 15476213)
Lancet. 2002 Jun 22;359(9324):2131-9. (PMID: 12090977)
Anticancer Drugs. 2004 Sep;15(8):753-60. (PMID: 15494636)
N Engl J Med. 2004 Mar 11;350(11):1081-92. (PMID: 15014181)
J Clin Endocrinol Metab. 2005 Jun;90(6):3215-24. (PMID: 15797954)
J Nutr. 2005 Feb;135(2):332-7. (PMID: 15671237)
J Clin Oncol. 2009 May 1;27(13):2151-6. (PMID: 19349547)
J Rheumatol. 1993 Mar;20(3):557-60. (PMID: 8478873)
Lancet. 2007 Feb 17;369(9561):559-70. (PMID: 17307102)
Semin Oncol. 1996 Aug;23(4 Suppl 9):10-20. (PMID: 8824460)
Maturitas. 1996 Jul;24(3):161-75. (PMID: 8844630)
N Engl J Med. 2007 Jul 19;357(3):266-81. (PMID: 17634462)
N Engl J Med. 1998 Mar 19;338(12):777-83. (PMID: 9504937)
J Clin Oncol. 2007 Sep 1;25(25):3877-83. (PMID: 17761973)
Am J Clin Nutr. 2004 Sep;80(3):752-8. (PMID: 15321818)
Am J Clin Nutr. 2003 Nov;78(5):912-9. (PMID: 14594776)
N Engl J Med. 1992 Dec 3;327(23):1637-42. (PMID: 1331788)
Lancet. 2005 Jan 1-7;365(9453):60-2. (PMID: 15639680)
Br J Cancer. 2005 Aug;93 Suppl 1:S16-22. (PMID: 16100521)
Mayo Clin Proc. 2003 Dec;78(12):1463-70. (PMID: 14661675)
J Clin Oncol. 2007 Feb 10;25(5):486-92. (PMID: 17200148)
J Clin Oncol. 2008 Feb 1;26(4):556-62. (PMID: 18180462)
معلومات مُعتمدة: K12 HD052027 United States HD NICHD NIH HHS
المشرفين على المادة: 0 (Antineoplastic Agents)
0 (Aromatase Inhibitors)
0 (Nitriles)
0 (Triazoles)
1406-16-2 (Vitamin D)
7LKK855W8I (Letrozole)
A288AR3C9H (25-hydroxyvitamin D)
تواريخ الأحداث: Date Created: 20090806 Date Completed: 20100222 Latest Revision: 20220409
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC4182952
DOI: 10.1007/s10549-009-0495-x
PMID: 19655244
قاعدة البيانات: MEDLINE
الوصف
تدمد:1573-7217
DOI:10.1007/s10549-009-0495-x